This measure of how well controlled your psoriatic arthritis is can be used to guide treatment decisions.

Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it ...

As rheumatologists prepare for EULAR 2026, Clinical Trials Arena takes a look at the most promising drugs in late-stage development for PsA.

Dragonfly Therapeutics, a clinical-stage biopharmaceutical company pioneering novel immunotherapies, today announced that the first patients have been successfully dosed subcutaneously (SC) with its ...

Introduction: The introduction of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has improved healthcare and health outcomes in patients with rheumatic ...

Adding a dual GLP-1/GIP receptor agonist to the psoriasis drug ixekizumab (Taltz) significantly improved outcomes in adults ...

Investigators compared the risk for overall infection, serious infection, and infections of special interest in patients with psoriasis receiving biologics or oral small molecules.

COSENTYX offers growth opportunities due to a large patient base fueling recurring revenue, robust global demand, double-digit growth, and an expanding label across multiple inflammatory conditions.

Johnson & Johnson's JNJ Immunology franchise remains one of its most important businesses, even as it undergoes a transition ...

Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...

Aboard Air Force One (AFP) | 15/05/2026 - 13:11:51 | Trump says Xi 'feels strongly' Iran can't have nuclear weapon ...

Vyome has signed an agreement with Impetis, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market¹These next-generation JAK ...